Biotron Limited · ASX:BIT
Biotron — Investor Presentation (November 2021)
17 slides from Biotron's investor presentation, Nov 25, 2021
Slide 1: Investor Update
BIOTRON LIMITED (ASX:BIT) INVESTOR UPDATE 25 November 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Biotron Limited (ASX:BIT) Overview
Biotron Limited (ASX:BIT) Overview • Clinical stage company developing small molecule drugs targeting viral diseases with major health problems: • HIV-1 , COVID-19, Hepatitis B virus and others • Unique approach to tackling virus infections • Combining direct antiviral and immunomodulatory activitie
Slide 4: Biotron's Core Technology/Expertise
Biotron’s Core Technology/Expertise • Targeting a key viral protein class found on a range of different viruses • Known as viroporins – these proteins determine how efficiently a virus infects cells and evades the immune system • The HIV-1 program, including a successful, completed, Phase 2 HIV-1 cl
Slide 5: SARS-CoV-2
SARS-CoV-2 • Biotron’s approach has been to design new small molecule drugs that target the SARS-CoV-2 viroporin(s) • E protein is a viroporin • Multiple roles in the virus lifecycle • Entry into cells and exit of new virus particles from infected cells • Pathogenesis of disease resulting from the i
Slide 6: SARS-CoV-2 Program
SARS-CoV-2 Program Vaccines remain central to control of the pandemic but there is an urgent need for effective drugs to treat COVID in at-risk populations • Since start of pandemic Biotron’s focus has been on designing and testing new compounds to target the SARS-CoV-2 E protein (oral drugs) based
Slide 7: K18-hACE2: Mouse Model of COVID-19
K18-hACE2: Mouse Model of COVID-19 • K18-hACE2 mouse model of COVID-19: • Mice engineered to express human ACE2 – the receptor used by SARS-CoV-2 to enter cells • Infection with SARS-CoV-2 results in a dose-dependent lethal disease • Rapid weight loss • Shed high levels of virus from respiratory tra
Slide 8: BIT225 – Mouse Model of COVID-19 Study
BIT225 – Mouse Model of COVID-19 Study BIT225 (100mg/kg and 300 mg/kg) administered via oral gavage, BID for 7 days versus vehicle control the in K18-hACE2 transgenic mouse model: • Virus strain: 2019n-CoV/USA-WA1/2020 • Infectious dose: 104 pfu intranasal, administered after second drug dose • Numb
Slide 9: Protected Against Severe Disease
BIT225 Protected Against Severe Disease Significant differences in % body weight change from Day 1 The increase in weight of mice treated with BIT225, compared to the decrease in weight of mice treated with vehicle control, indicates a reduction in the severity of disease and complications associate
Slide 10: Significantly Reduced “Cytokine Storm”
BIT225 Significantly Reduced “Cytokine Storm” Assessment of pro-inflammatory cytokines/chemokines in lungs For all six cytokines, the high dose of BIT225 is associated with significant reduction in lung tissue compared to mice treated with vehicle control. In addition, the high dose of BIT225 has gr
Slide 11: Significantly Reduced “Cytokine Storm”
BIT225 Significantly Reduced “Cytokine Storm” Assessment of pro-inflammatory cytokines/chemokines in blood For all six cytokines, the high dose of BIT225 is associated with significant reduction in blood compared to mice treated with vehicle control. In addition, the high dose of BIT225 has greater
Slide 12: Significantly Reduced Virus Levels in Lungs & Blood
BIT225 Significantly Reduced Virus Levels in Lungs & Blood Virus levels in lungs and blood showed that both doses of BIT225 significantly reduced viral load compared to vehicle control. There was a dose-dependent effect with BIT225. Plots show data values for each mouse, with median (line) and mean
Slide 13: BIT225 – Summary of Mouse Study
BIT225 – Summary of Mouse Study • BIT225 demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in this animal model of COVID-19: • Significantly inhibits SARS-CoV-2 replication and reduces infectious viral load in lungs and blood • Significantly reduces the production of pro
Slide 14: BIT225 – Extensive Clinical Trial Experience
BIT225 – Extensive Clinical Trial Experience • BIT225 is a small molecule, antiviral drug that is in capsule form for oral dosing • Suitable for once daily dosing • BIT225 is in development for HIV-1 eradication and improving health outcomes associated with immune dysfunction • Two Phase 2 trials ar
Slide 15: BIT225 – Moving Quickly to Assess in Human COVID Study(s)
BIT225 – Moving Quickly to Assess in Human COVID Study(s) • In discussions with international advisors to design clinical study(s) to assess efficacy against COVID • Engaging with relevant regulators (FDA/CTAP) to facilitate fast assessment • Aim is to progress BIT225 into trials to assess efficacy
Slide 16: Summary
SUMMARY • BIT225 demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 infection in an animal model of COVID-19 • It is active against the highly infectious delta strain in cell cultures • BIT225 is a clinical stage drug in development for treatment of HIV-1, with over 200 p
Slide 17: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller, PhD CEO & Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329